Overview

Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

Status:
Not yet recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

The purpose of this study if to evaluate the efficacy and safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.

Phase:

Phase 3

Details

Lead Sponsor:

EMS

Treatments:

Butylscopolammonium Bromide